Drug Insights

Is Pluvicto approved by the FDA?

24 July 2024
2 min read

Pluvicto, whose generic name is lutetium Lu 177 vipivotide tetraxetan, received FDA approval for its indicated use in adult patients with PSMA-positive mCRPC. Pluvicto This approval allows its use in patients who have previously undergone treatment with other anti-cancer therapies, indicating its efficacy in managing advanced stages of this specific type of prostate cancer.

How Pluvicto Works

Before administering Pluvicto, patients typically undergo imaging using PSMA-11 imaging agents like Locametz to identify PSMA-positive lesions. This step helps ensure targeted treatment delivery to affected areas, optimizing therapeutic outcomes.

Safety Considerations and Warnings

While effective, Pluvicto comes with significant safety precautions due to its nature as a radiopharmaceutical:

  • Radiation Exposure: Pluvicto contributes to long-term cumulative radiation exposure, which is managed through strict protocols to minimize risks to patients and caregivers.
  • Reproductive Risks: It may cause harm to unborn babies, necessitating effective contraception during treatment and for a specified period afterward.
  • Myelosuppression: This condition, marked by reduced blood cell counts, and renal toxicity are serious potential side effects. Patients undergo regular monitoring and may require supportive care to manage these risks effectively.

Administration and Dosage

Pluvicto is administered intravenously every six weeks for a maximum of six doses or until disease progression or unacceptable toxicity occurs. Patients are advised to maintain hydration and follow specific post-administration precautions to minimize radiation exposure to others.

Side Effects

Common side effects of Pluvicto include fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Patients should promptly report any signs of myelosuppression or renal toxicity to their healthcare provider.

Drug Interactions

Pluvicto is not known to interact significantly with other medications, though patients should disclose all current medications, including over-the-counter drugs, vitamins, and herbal supplements, to their healthcare provider before treatment initiation.

In conclusion, Pluvicto represents a targeted therapeutic option approved by the FDA for managing PSMA-positive mCRPC in adults who have exhausted other treatment options. Its approval underscores its role in addressing advanced prostate cancer, highlighting ongoing advancements in oncological care.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Bayer Announces Promising NUBEQA® Phase III Results in Metastatic Hormone-Sensitive Prostate Cancer
Latest Hotspot
2 min read
Bayer Announces Promising NUBEQA® Phase III Results in Metastatic Hormone-Sensitive Prostate Cancer
24 July 2024
Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Read →
Is Nivolumab/Relatlimab approved by the FDA?
Drug Insights
2 min read
Is Nivolumab/Relatlimab approved by the FDA?
24 July 2024
Nivolumab and relatlimab received FDA approval for the treatment of unresectable or metastatic melanoma on March 18, 2022.
Read →
Is Ganaxolone approved by the FDA?
Drug Insights
3 min read
Is Ganaxolone approved by the FDA?
24 July 2024
Ganaxolone, marketed under the brand name Ztalmy, is FDA approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in individuals aged 2 years and older.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 23
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 23
23 July 2024
Jul 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.